

Supplementary Material

Experimental

General

NMR spectra were recorded on 400 MHz or 300 MHz Bruker instruments. Chemical shifts were reported in ppm (parts per millions) using the solvent residual peak as the internal reference. IR spectra were recorded on a Perkin Elmer 1600 series. Chemical shifts are referenced to the residual solvent peak. Quin = quintet, sext = sextuplet, Septuplet = sept, double septuplets = dsept, octuplet = oct. TLC was performed on Merck TLC aluminium sheets, silica gel 60, F254 and visualizing was effected with UV-light and/or 1 % ninhydrin in n-BuOH/AcOH. High resolution mass spectra were provided by the Department of Bioorganic Chemistry, Royal Veterinary and Agricultural University, Denmark. Elemental analysis was provided by the Department of Chemistry, University of Copenhagen, Denmark. Dry Flash Chromatography was performed with silica gel using Merck Silica gel 60 (0.015–0.040 mm). PtO₂ (surface area ≥60 m²/g) was purchased from SigmaAldrich Denmark. All solvents were purchased from VWR and used without further purification and kept under MS and a nitrogen atmosphere. Pyrrolidinediones were synthesized as previously described¹. Molecular sieves was purchased from VWR and used as received with no activation.

pyAla-Ala-NH₂ (**3a**)

To a solution of (S)-5-methylpyrrolidine-2,4-dione (*pyAla-OH*)¹ (226 mg, 2.0 mmol) in i-PrOH (9 mL) was added AcOH (1 mL), alanine amide (125 mg, 1.0 mmol) and 3 Å molecular sieves (5 mL). The mixture was heated to 55 °C and stirred for 24h. The red-brown mixture was filtered through celite and evaporated to a brown oil. Purification by dry flash chromatography using a gradient eluent of 0–10 vol% MeOH in EtOAc (150 ml fractions) provided the title product as an off-white solid (174 mg, 95%). ¹H NMR (400 MHz, CD₃OD) δ 4.52 (s, 1H), 4.10 (q, *J* = 6.6 Hz, 1H), 3.81 (q, *J* = 7.1 Hz, 1H), 1.44 (d, *J* = 7.1 Hz, 3H), 1.36 (d, *J* = 6.6 Hz, 3H). ¹³C NMR (100 MHz, CD₃OD) δ 18.6, 19.8, 55.0, 55.3, 87.3, 170.3, 177.9, 179.1. IR (KBr): 3297 (br) 1681 (s), 1606 (s), 1608 (s), 1206 (w), 792 (w). Mp 89–90 °C. [α]²⁰_D 35.7 (*c* 0.1, MeOH). HRMS (EI⁺): Calcd. for C₈H₁₄N₃O₂ [M+H⁺] 184.1086 Found 184.1085.

pyAla-Val-NH₂ (**3b**)

Following the procedure for **3a** (186 mg, 88%).

¹H NMR (300 MHz, DMSO) δ 7.36 (bs, 1H), 7.07 (bs, 1H), 6.73 (bs, 1H), 6.47 (d, *J* = 8.3 Hz, 1H), 4.34 (s, 1H), 3.87 (q, *J* = 6.4 Hz, 1H), 1.95 (sept, *J* = 6.8 Hz, 1H), 1.18 (d, *J* = 6.4 Hz, 3H), 0.93–0.87 (m, 6H). ¹³C NMR (75 MHz, DMSO) δ 19.0, 19.2, 19.9, 30.2, 52.0, 64.0, 86.1, 167.8, 172.9, 174.9. IR (KBr): 3413 (br) 2926 (w), 1676 (s), 1608 (s), 1207 (s), 1137 (s). [α]²⁰_D -88.0 (*c* 0.3, MeOH). HRMS (EI⁺): Calcd. for C₁₀H₁₈N₃O₂ [M+H⁺] 212.1399 Found 212.1409.

pyAla-Leu-NH₂ (**3c**)

Following the procedure for **3a** (191 mg, 85%).

¹H NMR (400 MHz, CD₃OD) δ 4.49 (s, 1H), 4.12 (q, *J* = 6.6 Hz, 1H), 3.73 (dd, *J* = 5.1, 8.6 Hz, 1H), 1.65–1.47 (m, 3H), 1.24 (d, *J* = 7.1 Hz, 3H), 0.83 (d, *J* = 6.6 Hz, 3H), 0.79 (d, *J* = 6.6 Hz, 3H). ¹³C NMR (100 MHz, CD₃OD) δ 19.9, 22.3, 23.5, 26.1, 42.5, 54.8, 58.5, 87.0, 170.7, 177.9, 179.0. IR (KBr): 3391 (br), 1674 (s), 1605 (s), 1203 (w), 722 (w). Mp 127–129 °C. [α]²⁰_D -150.0 (*c* 0.4, MeOH). HRMS (EI⁺): Calcd. for C₁₁H₂₀N₃O₂ [M+H⁺] 226.1559 Found 226.1557.

pyVal-Ala-NH₂ (**3d**)

Following the procedure for **3a** (186 mg, 88%).

¹H NMR (400 MHz, CD₃OD) δ 0.71 (m, *J* = 6.6 Hz, 3H), 1.08 (d, *J* = 7.1 Hz, 3H), 1.43 (d, *J* = 6.6 Hz, 3H), 2.14 (dsept, *J* = 7.1, 2.5 Hz, 1H), 3.82 (q, *J* = 7.1 Hz, 1H), 4.03 (d, *J* = 2.5 Hz, 1H), 4.56 (s, 1H). ¹³C NMR (100 MHz, CD₃OD) δ 13.9, 18.4, 20.7, 31.5, 49.5, 54.9, 64.1, 88.5, 167.9, 177.8, 180.1. IR (KBr): 3400 (br), 1679 (s), 1642 (s), 1609 (s), 729 (w). Mp 102–104 °C. [α]²⁰_D -22.4 (*c* 0.7, MeOH). HRMS (EI⁺): Calcd. for C₁₀H₁₈N₃O₂ [M+H⁺] 212.1399 Found 212.1396.

pyVal-Val-NH₂ (**3e**)

Following the procedure for **3a** (196 mg, 82%).

¹H NMR (400 MHz, CD₃OD) δ 0.67 (d, *J* = 6.6 Hz, 3H), 1.01 (d, *J* = 6.6 Hz, 3H), 1.04 (d, *J* = 6.6 Hz, 3H), 1.07 (d, *J* = 6.6 Hz, 3H), 2.04 (sept, *J* = 6.9 Hz, 1H), 2.16 (dsept, *J* = 6.8, 2.8 Hz, 1H), 3.45 (d, *J* = 8.6 Hz, 1H), 4.07 (d, *J* = 3.0 Hz, 1H), 4.63 (s, 1H). ¹³C NMR (100 MHz, CD₃OD) δ 13.8, 19.5, 19.6, 20.8, 31.5, 32.0, 63.9, 65.7, 88.1, 168.7, 176.3,

Supplementary Material for Organic & Biomolecular Chemistry
This journal is (c) The Royal Society of Chemistry 2007

180.3. IR (KBr): 3429 (br), 2976 (w), 1670 (s), 1288 (w). Mp 102–104 °C. $[\alpha]^{20}_D -84.4$ (*c* 1.2, MeOH). HRMS (EI⁺): Calcd. for C₁₂H₂₂N₃O₂ [M+H⁺] 240.1712 Found 240.1708.

*py*Val-Leu-NH₂ (**3f**)

Following the procedure for **3a** (231 mg, 91%).

¹H NMR (400 MHz, CD₃OD) δ 0.69 (d, *J* = 6.6 Hz, 3H), 0.94 (d, *J* = 6.6 Hz, 3H), 0.98 (d, *J* = 6.1 Hz, 3H), 1.07 (d, *J* = 7.1 Hz, 3H), 1.54–1.62 (m, 1H), 1.66–1.67 (m, 2H), 2.17 (dsept, *J* = 6.9, 2.8 Hz, 1H), 3.79 (dd, *J* = 8.6, 5.6 Hz, 1H), 4.04 (d, *J* = 2.5 Hz, 1H), 4.62 (s, 1H). ¹³C NMR (100 MHz, CD₃OD) δ 13.8, 20.8, 22.3, 23.3, 26.0, 31.4, 42.5, 58.1, 64.0, 88.1, 168.5, 177.6, 180.2. IR (KBr): 3273 (br), 2398 (m), 1655 (s), 1602 (s), 155 (w). Mp 118–119 °C. $[\alpha]^{20}_D -21.6$ (*c* 0.9, MeOH). HRMS (EI⁺): Calcd. for C₁₃H₂₄N₃O₂ [M+H⁺] 254.1869 Found 254.1866.

*py*Val-D-Ala-NH₂ (**3g**)

Following the procedure for **3a** (177 mg, 84%).

¹H NMR (300 MHz, DMSO) δ 7.42 (bs, 1H), 7.08 (bs, 1H), 6.86 (bs, 1H), 6.61 (d, *J* = 7.5 Hz, 1H), 4.31 (s, 1H), 3.84 (bs, 1H), 3.60 (quin, *J* = 7.1 Hz, 1H), 2.06 (dsept, *J* = 6.8, 2.6 Hz, 1H), 1.25 (d, *J* = 6.8 Hz, 3H), 0.95 (d, *J* = 0.95 Hz, 3H), 0.56 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (75 MHz, DMSO) δ 13.4, 18.2, 20.2, 29.2, 53.0, 61.3, 88.0, 164.6, 174.4, 175.8. IR (KBr): 3292 (br) 2963 (w), 1648 (s), 1609 (s), 1158 (w). Mp 232–234 °C.

$[\alpha]^{20}_D -31.8$ (*c* 0.7, MeOH). HRMS (EI⁺): Calcd. for C₁₀H₁₈N₃O₂ [M+H⁺] 212.1393 Found 212.1399.

*py*Val-Ala-OMe (**3h**)

Following the procedure for **3a** (198 mg, 88%).

¹H NMR (400 MHz, CD₃OD) δ 4.48 (s, 1H), 4.02 (d, *J* = 3.0 Hz, 1H), 3.98 (dq, *J* = 2.5, 7.1 Hz, 1H), 2.14 (dsept, *J* = 3.0, 6.6 Hz, 1H), 1.45 (d, *J* = 7.1 Hz, 3H), 1.08 (d, *J* = 7.1 Hz, 3H), 0.73 (d, *J* = 6.6 Hz, 3H).

¹³C NMR (100 MHz, CD₃OD) δ 13.7, 17.5, 17.6, 20.7, 31.4, 52.7, 54.0, 64.0, 88.1, 168.0, 174.7, 180.1.

IR (KBr): 3435 (br), 1640 (m), 1635 (m), 1120 (w). Mp 181–182 °C. $[\alpha]^{20}_D -101.9$ (*c* 0.5, MeOH).

HRMS (EI⁺): Calcd. for C₁₁H₂₁N₂O₃ [M+H⁺] 226.1552 Found 226.1552.

*py*Val-Ala-Ot-Bu (**3i**)

Following the procedure for **3a** (250 mg, 93%).

¹H NMR (400 MHz, CD₃OD) δ 4.51 (s, 1H), 4.01 (d, *J* = 2.5 Hz, 1H), 3.79 (q, *J* = 7.1 Hz, 1H), 2.15 (dsept, *J* = 2.5, 7.1 Hz, 1H), 1.46 (s, 9H), 1.41 (d, *J* = 7.1 Hz, 3H), 1.08 (d, *J* = 7.1 Hz, 3H), 0.75 (d, *J* = 7.1 Hz, 3H).

¹³C NMR (100 MHz, CD₃OD) δ 4.0, 17.62, 17.57, 20.7, 28.2, 31.4, 55.0, 55.1, 63.9, 64.0, 82.8, 88.00, 88.05, 168.0, 168.1, 173.7, 180.2. IR (KBr): 3392 (w), 2980 (w), 1604 (s), 1369 (m), 1148 (m). Mp 164–165 °C. $[\alpha]^{20}_D 177.5$ (*c* 0.5, MeOH). HRMS (EI⁺): Calcd. for C₁₄H₂₅N₂O₃ [M+H⁺] 269.1865 Found 269.1854.

*py*Val-Pro-NH₂ (**3j**)

Following the procedure for **3a** (209 mg, 88%).

¹H NMR (400 MHz, DMSO) δ 4.29 (bs, 1H), 3.50–3.31 (m, 3H), 2.25–2.09 (m, 2H), 1.97–1.68 (m, 2H), 0.96 (d, *J* = 7.1 Hz, 3H), 0.58 (d, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, DMSO) δ 13.1, 20.1, 23.7, 28.0, 30.2, 49.3, 61.0, 62.4, 90.5, 164.3, 173.2, 174.7. IR (KBr): 3479 (w), 2964 (w), 1658 (s), 1592 (s), 1399 (m).

Mp 93–94 °C. $[\alpha]^{20}_D -33.3$ (*c* 0.5, MeOH). HRMS (EI⁺): Calcd. for C₁₂H₂₀N₃O₂ [M+H⁺] 238.1556 Found 238.1556.

*py*Leu-Ala-NH₂ (**3k**)

Following the procedure for **3a** (198 mg, 88%).

¹H NMR (400 MHz, CD₃OD) δ 4.52, (s, 1H), 4.11 (dd, *J* = 3.0, 10.6 Hz, 1H), 3.81 (q, *J* = 6.6 Hz, 1H), 1.85–1.74 (m, 1H), 1.85–1.72 (m, 1H), 1.42 (d, *J* = 7.1 Hz, 3H), 1.40–1.34 (m, 1H), 0.99 (d, *J* = 6.5 Hz, 3H), 0.97 (d, *J* = 6.6 Hz).

¹³C NMR (100 MHz, CD₃OD) δ 18.4, 21.6, 24.4, 26.4, 40.4, 44.1, 55.2, 57.6, 169.6, 177.9, 179.3. IR (KBr): 3398 (br) 2963 (w), 1682 (s), 1607 (s), 1207 (s), 1140 (s). Mp 132–135 °C. $[\alpha]^{20}_D -15.8$ (*c* 0.4, MeOH). HRMS (EI⁺): Calcd. for C₁₁H₂₀N₃O₂ [M+H⁺] 226.1556 Found 226.1547.

*py*Leu-Val-NH₂ (**3l**)

Following the procedure for **3a** (218 mg, 86%).

¹H NMR (400 MHz, CD₃OD) δ 4.55 (s, 1H), 4.12–4.08 (m, 1H), 4.42–3.38 (m, 1H), 2.05–1.91 (m, 1H), 1.75–1.59 (m, 2H), 1.32–1.15 (m, 1H), 1.01–0.85 (m, 12H). ¹³C NMR (100 MHz, CD₃OD) δ 19.4, 19.6, 21.7, 24.4, 26.3, 32.0, 44.0, 57.5, 66.0, 87.1, 170.3, 170.4, 176.4, 179.3. IR (KBr): 3403 (br), 2966 (w), 1677 (s), 1603 (s), 1415 (m). Mp 105–106 °C. $[\alpha]^{20}_D -27.7$ (*c* 0.3, MeOH). HRMS (EI⁺): Calcd. for C₁₃H₂₄N₃O₂ [M+H⁺] 254.1869 Found 254.1873.

*py*Leu-Leu-NH₂ (**3m**)

Following the procedure for **3a** (233 mg, 87%).

Supplementary Material for Organic & Biomolecular Chemistry
This journal is (c) The Royal Society of Chemistry 2007

¹H NMR (400 MHz, CD₃OD) δ 4.60 (s, 1H), 4.14 (dd, *J* = 2.5, 10.1 Hz, 1H), 3.79 (dd, *J* = 8.6, 5.6 Hz, 1H), 1.83–1.67 (m, 4H), 1.64–1.56 (m, 1H), 1.02–0.91 (m, 12H). ¹³C NMR (100 MHz, CD₃OD) δ 21.6, 22.2, 23.3, 24.4, 25.9, 26.3, 42.3, 44.0, 57.6, 57.6, 58.3, 87.1, 170.0, 177.8, 179.3. IR (KBr): 3420 (br) 2962 (w), 1677 (s), 1606 (s), 1202 (s), 1142 (s). Mp 132–133 °C. [α]²⁰_D -25.6 (*c* 0.3, MeOH). HRMS (EI⁺): Calcd. for C₁₄H₂₆N₃O₂ [M+H⁺] 268.2025 Found 268.2012.

*cis*pyPhe-Leu-NH₂ (**3n**)

Following the procedure for **3a** (1592 mg, 88%).

¹H NMR (300 MHz, CD₃OD) δ 7.30–7.20 (m, 5H), 4.50 (s, 1H), 4.33 (dd, *J* = 3.8, 7.1 Hz, 1H), 3.76 (dd, *J* = 5.6, 8.5 Hz, 1H), 2.24 (dd, *J* = 4.1, 13.8 Hz, 1H), 2.82 (dd, *J* = 7.0, 13.8 Hz, 1H), 1.81–1.56 (m, 3H), 0.99 (d, *J* = 6.4 Hz, 3H), 0.95 (d, *J* = 6.5 Hz, 3H).

¹³C NMR (75 MHz, CD₃OD) δ 22.1, 22.8, 24.3, 38.5, 41.0, 56.3, 57.0, 87.3, 126.1, 127.7, 129.9, 136.8, 164.9, 173.9, 175.0. IR (KBr): 3459 (br), 2925 (m), 1675 (m), 1601 (m). Mp 168–169 °C.

[α]²⁰_D 86.9 (*c* 0.6, MeOH). Anal. Calcd. for C₁₇H₂₃N₃O₂: C, 67.75; H, 7.69. N, 13.94 Found: C, 67.40; H, 7.54; N, 13.58.

*cis*pyAla-Ala-NH₂ (**4a**)

To a solution of **3a** (0.109mmol, 20 mg) in *t*-BuOH (2 mL) was added PtO₂ (6 mg, 0.026mmol). The mixture was heated to 25 °C and stirred under 60 bar H₂ for 24 h. Filtration of the catalyst followed by evaporation provided the title product as a white solid (18 mg, 89%).

¹H NMR (400 MHz, CD₃OD) δ 3.81 (quint, *J* = 6.6 Hz, 1H), 3.53–3.46 (m, 1H), 3.18 (q, *J* = 7.1 Hz, 1H), 2.39 (dd, *J* = 8.1, 16.7 Hz, 1H), 2.22 (dd, *J* = 9.6, 16.7 Hz, 1H), 1.27 (d, *J* = 7.1 Hz, 3H), 1.14 (d, *J* = 6.6 Hz, 3H).

¹³C NMR (75 MHz, CD₃OD) δ 181.1, 177.5, 56.9, 56.2, 53.6, 36.6, 19.6, 15.2. IR (KBr): 3435 (br) 2860 (w), 1650 (m). [α]²⁰_D -52.2 (*c* 0.4, MeOH). HRMS (EI⁺): Calcd. for C₈H₁₆N₃O₂ [M+H⁺] 186.1243 Found 186.1234.

*cis*pyAla-Val-NH₂ (**4b**)

To a solution of **3d** (0.095mmol, 20 mg) in *t*-BuOH (2 mL) was added PtO₂ (5 mg, 0.022mmol). The mixture was heated to 25 °C and stirred under 60 bar H₂ for 36h. Filtration of the catalyst followed by column chromatography (EtOAc/MeOH, 9:1) (18 mg, 89%).

¹H NMR (400 MHz, CD₃OD) δ 3.78 (quint, *J* = 6.6 Hz, 1H), 3.47–3.39 (m, 1H), 2.23 (d, *J* = 6.6 Hz, 1H), 2.37 (dd, *J* = 8.8, 16.7 Hz, 1H), 2.24 (dd, *J* = 9.6, 16.7 Hz, 1H), 1.81 (oct, *J* = 6.6 Hz, 1H), 1.15 (d, *J* = 6.6 Hz, 3H), 1.02 (d, *J* = 7.1 Hz, 3H), 1.02 (d, *J* = 7.1 Hz, 3H), 0.98 (d, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CD₃OD) δ 15.7, 19.4, 19.9, 33.0, 37.1, 54.2, 56.9, 68.1, 178.2, 180.1. IR (KBr): 3435 (br) 2925 (w), 1677 (s), 1435 (w), 1206 (w). [α]²⁰_D 32.6 (*c* 0.7, MeOH). HRMS (EI⁺): Calcd. for C₁₀H₂₀N₃O₂ [M+H⁺] 215.1556 Found 215.1559.

*cis*pyAla-Leu-NH₂ (**4c**)

Following the procedure for **4a** (19 mg, 94%).

¹H NMR (400 MHz, CD₃OD) δ 3.79 (quint, *J* = 6.6 Hz, 1H), 3.45–3.42 (m, 1H), 3.15 (t, *J* = 7.1 Hz, 1H), 2.38 (dd, *J* = 8.1, 16.7 Hz, 1H), 2.22 (dd, *J* = 9.6, 16.7 Hz, 1H), 1.77 (sept, *J* = 6.6 Hz, 1H), 1.48–1.40 (m, 2H), 1.13 (d, *J* = 6.6 Hz, 3H), 0.95 (d, *J* = 6.6 Hz, 3H), 0.93 (d, *J* = 6.6 Hz, 3H). ¹³C NMR (100 M Hz, CD₃OD) δ 15.8, 23.3, 23.4, 26.2, 37.3, 44.9, 54.4, 56.9, 61.0, 178.3, 181.3. IR (KBr): 3439 (br), 2960 (w), 1672 (s), 1435 (w), 1204 (m). [α]²⁰_D -32.0 (*c* 0.05, MeOH). HRMS (EI⁺): Calcd. for C₁₁H₂₂N₃O₂ [M+H⁺] 228.1712 Found 228.1720.

*cis*pyVal-Ala-NH₂ (**4d**)

To a solution of **3d** (0.095mmol, 20 mg) in *t*-BuOH (2 mL) was added PtO₂ (5 mg, 0.022mmol). The mixture was heated to 55 °C and stirred under 60 bar H₂ for 24h. Filtration of the catalyst followed by evaporation provided the title product as a white solid (19 mg, 94%).

¹H NMR (400 MHz, CD₃OD) δ 3.62 (q, *J* = 7 Hz, 1H), 3.52 (t, *J* = 7 Hz, 1H), 3.30 (q, *J* = 7 Hz, 1H), 2.45 (dd, *J* = 6 Hz, 16 Hz, 1H), 2.20 (dd, *J* = 6, 16 Hz, 1H), 2.93 (oct, *J* = 6 Hz, 1H), 1.25 (d, *J* = 7 Hz, 3H), 0.93 (d, *J* = 7 Hz, 3H), 0.85 (d, *J* = 7 Hz, 3H). ¹³C NMR (100 MHz, CD₃OD) δ 17.7, 21.7, 25.3, 29.8, 32.2, 36.8, 55.5, 64.1, 65.6, 67.7, 178.7, 181.6. IR (KBr): 3390 (br), 2966 (w), 1682 (s), 1385 (w). [α]²⁰_D 37.5 (*c* 0.5, MeOH). HRMS (EI⁺): Calcd. for C₁₀H₂₀N₃O₂ [M+H⁺] 214.1556 Found 214.1548.

*cis*pyVal-Val-NH₂ (**4e**)

Following the procedure for **4d** (20 mg, 99%).

¹H NMR (400 MHz, CD₃OD) δ 3.50–3.43 (m, 2H), 2.79 (d, *J* = 7.6 Hz, 1H), 2.39 (dd, *J* = 7.1, 16.7 Hz, 1H), 2.25 (dd, *J* = 7.1, 16.2 Hz, 1H), 2.14–2.03 (m, 1H), 1.78 (oct, *J* = 6.6 Hz, 1H), 1.01 (d, *J* = 6.6 Hz, 3H), 0.97 (d, *J* = 6.1 Hz, 6H).

¹³C NMR (100 MHz, CD₃OD) δ 18.3, 19.3, 19.9, 20.7, 29.3, 33.1, 38.9, 57.2, 64.9, 68.7, 179.3, 180.5. IR (KBr): 3429 (br) 2976 (w), 1670 (s), 1209 (w), 672 (w). Mp 178–179 °C. [α]²⁰_D -25.2 (*c* 0.5, MeOH). HRMS (EI⁺): Calcd. for C₁₂H₂₄N₃O₂ [M+H⁺] 242.1869 Found 242.1859.

cis-*p*yVal-Leu-NH₂ (**4f**)

Following the procedure for **4d** (19 mg, 94%).

¹H NMR (400 MHz, D₂O) δ 3.61 (q, *J* = 7.1 Hz, 1H), 3.59–3.52 (m, 1H), 3.10 (t, *J* = 7.6 Hz, 1H), 2.46 (dd, *J* = 7.1, 16.7 Hz, 1H), 2.21 (dd, *J* = 7.6, 16.7 Hz, 1H), 1.91 (quint, *J* = 6.6 Hz, 1H), 1.55 (quint, *J* = 6.6 Hz, 1H), 1.47–1.40 (m, 1H), 0.91–0.83 (m, 12H). ¹³C NMR (100 MHz, CD₃OD) δ 18.4, 20.7, 22.9, 23.4, 25.9, 29.3, 38.9, 44.7, 57.0, 61.2, 64.9, 179.3, 181.5. IR (KBr): 3378 (br), 2964 (w), 1639 (s), 1390 (w). Mp 170–172 °C [α]²⁰_D 162.6 (*c* 0.5, MeOH). HRMS (EI⁺): Calcd. for C₁₃H₂₆N₃O₂ [M+H⁺] 256.2025 Found 256.2028.

cis-*p*yVal-D-Ala-NH₂ (**4g**)

Following the procedure for **4d** (20 mg, 99%).

¹H NMR (400 MHz, CD₃OD) δ 3.41–3.35 (m, 2H), 3.24 (q, *J* = 6.6 Hz, 1H), 2.46 (dd, *J* = 6.6, 16.7 Hz, 1H), 1.97 (sext, *J* = 7.1 Hz, 1H), 1.26 (d, *J* = 6.6 Hz, 3H), 1.02–0.97 (m, 6H). ¹³C NMR (400 MHz, CD₃OD) δ 18.66, 18.73, 19.4, 26.6, 37.5, 53.7, 54.1, 65.0, 180.1, 180.2. IR (KBr): 3351 (br), 2976 (w), 1670 (s), 1385 (w), 1209 (w). [α]²⁰_D 40.1 (*c* 0.2, MeOH). HRMS (EI⁺): Calcd. for C₁₀H₂₀N₃O₂ [M+H⁺] 214.1556 Found 214.1558.

cis-*p*yVal-Ala-OMe (**4h**)

Following the procedure for **4d** (20 mg, 99%).

¹H NMR (400 MHz, CD₃OD) δ 3.72 (s, 3H), 3.54–3.33 (m, 3H), 2.39 (dd, *J* = 8.1, 16.7 Hz, 1H), 2.21 (dd, *J* = 7.1, 16.7, 1H), 2.05–1.96 (m, 1H), 1.27 (d, *J* = 7.1 Hz, 3H), 0.95 (d, *J* = 6.6 Hz, 6H).

¹³C NMR (100 MHz, CD₃OD) δ 18.5, 19.2, 20.6, 29.3, 38.8, 52.5, 56.3, 56.7, 65.0, 177.8, 179.3.

IR (KBr): 3435 (s), 2923 (w), 1732 (m), 1688 (m), 1175 (w).

Mp 68–70 °C. [α]²⁰_D −51.5 (*c* 0.6, MeOH), HRMS (EI⁺): Calcd. for C₁₁H₂₀N₂NaO₃ [M+Na⁺] 251.1372 Found 251.1369.

cis-*p*yVal-AlaOt-Bu (**4i**)

Following the procedure for **4d** (19 mg, 94%).

¹H NMR (400 MHz, CD₃OD) δ 3.64–3.54 (m, 2H), 3.32 (q, *J* = 6.6 Hz, 1H), 2.43 (dd, *J* = 7.6, 16.8 Hz, 1H), 2.23 (dd, *J* = 8.1, 17.2 Hz, 1H), 1.97–1.86 (m, 1H), 1.42 (s, 9H), 1.23 (dd, *J* = 7.1 Hz, 3H), 0.89 (d, *J* = 7.1 Hz, 3H), 0.85 (d, *J* = 6.6 Hz, 3H). ¹³C NMR (400 MHz, D₂O) δ 17.4, 17.9, 20.2, 27.4, 27.5, 37.1, 54.9, 56.4, 63.2, 83.8, 176.8, 179.7. IR (KBr): 3436 (br), 2975 (m), 1699 (s), 1368 (w), 1152 (m). [α]²⁰_D 177.5 (*c* 0.5, MeOH). HRMS (EI⁺): Calcd. for C₁₄H₂₆N₂O₃Na [M+Na⁺] 293.1841 Found 293.1842.

cis-*p*yVal-Pro-NH₂ (**4j**)

Following the procedure for **4d** (20 mg, 99%).

¹H NMR (400 MHz, CD₃OD) δ 3.51 (dd, *J* = 2.1, 7.1 Hz, 1H), 3.45–3.36 (m, 1H), 3.29–3.21 (m, 2H), 2.50–2.41 (m, 3H), 1.86–1.79 (m, 3H), 0.98 (d, *J* = 7.1 Hz, 3H), 0.94 (d, *J* = 6.6 Hz, 3H). ¹³C NMR (100 MHz, CD₃OD) δ 17.7, 21.7, 25.3, 29.8, 32.2, 36.7, 55.5, 64.1, 65.6, 67.7, 178.7, 181.6. IR (KBr): 3435 (br), 2963 (w), 1672 (s), 1317 (w), 1094 (w). Mp 81–82 °C. [α]²⁰_D −33.3 (*c* 0.7, MeOH). HRMS (EI⁺): Calcd. for C₁₂H₂₂N₃O₂ [M+H⁺] 240.1710 Found 240.1712.

cis-*p*yLeu-Ala-NH₂ (**4k**)

To a solution of **3k** (0.089 mmol, 20 mg) in *t*-BuOH (2 mL) was added PtO₂ (5 mg, 0.022 mmol). The mixture was heated to 35 °C and stirred under 60 bar H₂ for 36 h. Filtration of the catalyst followed by column chromatography (EtOAc/MeOH, 9:1) (18 mg, 89%).

¹H NMR (400 MHz, CD₃OD) δ 3.79–3.72 (m, 1H), 3.57–3.49 (m, 1H), 3.17 (q, *J* = 6.6 Hz, 1H), 2.38 (dd, *J* = 7.6, 16.7 Hz, 1H), 2.23 (dd, *J* = 9.6, 16.7 Hz, 1H), 1.74–1.64 (m, 1H), 1.47–1.40 (m, 1H), 1.27 (d, *J* = 7.1 Hz, 3H), 0.99 (d, *J* = 6.6 Hz, 3H), 0.94 (d, *J* = 6.6 Hz, 3H). ¹³C NMR (100 MHz, CD₃OD) δ 19.6, 21.3, 24.3, 25.4, 37.0, 39.2, 56.0, 56.7, 57.0, 178.0, 180.9. IR (KBr): 3435 (br), 2924 (w), 1677 (m), 1206 (w). [α]²⁰_D −103.6 (*c* 0.3, MeOH). HRMS (EI⁺): Calcd. for C₁₁H₂₂N₃O₂ [M+H⁺] 228.1712 Found 228.1717.

cis-*p*yLeu-Val-NH₂ (**4l**)

Following the procedure for **4k** (17 mg, 84%).

¹H NMR (400 MHz, CD₃OD) δ 3.81 (quint, *J* = 6.6 Hz, 1H), 3.52–3.46 (m, 1H), 3.18 (q, *J* = 6.6 Hz, 1H), 2.39 (dd, *J* = 8.1, 16.7 Hz, 1H), 1.27 (d, *J* = 7.1 Hz, 3H), 1.14 (d, *J* = 6.6 Hz, 3H). ¹³C NMR (100 MHz, CD₃OD) δ 19.4, 19.9, 21.8, 24.4, 25.6, 33.1, 37.5, 39.5, 56.7, 57.5, 68.2, 178.5, 180.2. IR (KBr): 3434 (br), 2964 (w), 1676 (m), 1209 (m). 1140 (m). [α]²⁰_D 86.0 (*c* 0.4, MeOH). HRMS (EI⁺): Calcd. for C₁₃H₂₆N₃O₂ [M+H⁺] 256.2025 Found 256.2036.

cis-*p*yLeu-Leu-NH₂ (**4m**)

Following the procedure for **4k** (20 mg, 99%).

Supplementary Material for Organic & Biomolecular Chemistry
This journal is (c) The Royal Society of Chemistry 2007

¹H NMR (400 MHz, CD₃OD) δ 3.83–3.78 (m, 1H), 3.66–3.61 (m, 1H), 2.42 (dd, *J* = 7.6, 16.2 Hz, 1H), 2.31 (d, *J* = 9.2, 16.2 Hz, 1H), 1.87–1.64 (m, 2H), 1.58–1.38 (m, 3H), 1.36–1.22 (m, 1H), 1.02–0.88 (m, 12H). ¹³C NMR (100 MHz, CD₃OD) δ 21.5, 23.0, 23.1, 24.5, 25.6, 25.8, 36.5, 39.4, 43.7, 56.0, 56.8, 60.6, 163.0, 163.4, 177.5. IR (KBr): 3413 (br), 2962 (w), 1677 (s), 1206 (m), 1142 (m). [α]²⁰_D −91.8 (*c* 0.5, MeOH). HRMS (EI⁺): Calcd. for C₁₄H₂₈N₃O₂ [M+H⁺] 270.2182 Found 270.2181.

cis-pyCha-Leu-NH₂ (**4n**)

Following the procedure for **4a** (20 mg, 99%).

¹H NMR (400 MHz, CD₃OD) δ 3.79–3.73 (m, 1H), 3.46 (q, *J* = 7.1 Hz, 1H), 3.11 (t, *J* = 7.1 Hz, 1H), 2.35 (dd, *J* = 7.6, 16.2 Hz, 1H), 2.22 (dd, *J* = 9.6, 16.7, 1H), 1.90–1.65 (m, 6H), 1.44–1.25 (m, 9H), 0.95 (d, *J* = 6.6 Hz, 3H), 0.94 (d, *J* = 5.6 Hz, 3H). ¹³C NMR (100 MHz, CD₃OD) δ 23.0, 23.4, 25.9, 27.1, 27.4, 27.7, 33.4, 35.1, 35.8, 37.5, 38.0, 44.7, 55.8, 57.2, 60.7, 178.3, 181.2. IR (KBr): 3435 (br) 2922 (m), 1656 (s), 1449 (w).

[α]²⁰_D −100.0 (*c* 0.33, MeOH). Mp. 267 °C (decomp.)

HRMS (EI⁺): Calcd. for C₁₁H₂₀N₃O₂ [M+H⁺] 310.2495 Found 310.2494.

cis-pyVal-Ala-OH (**5**)

To a solution of **4i** (36 mg, 0.13 mmol) was added TFA (3 mL) and the mixture was stirred for 6 hours and evaporated in vacuo to provide *cis*-pyVal-AlaOH-TFA (42 mg, 96%).

¹H NMR (300 MHz, CD₃OD) δ 4.24 (q, *J* = 7.5 Hz, 1H), 4.09 (q, *J* = 7.2 Hz, 1H), 2.70 (q, *J* = 7.9, 17.3 Hz, 1H), 2.56 (q, *J* = 6.8, 17.3 Hz, 1H), 1.89 (sext, *J* = 6.4 Hz, 1H), 1.53 (d, *J* = 7.2 Hz, 3H), 0.90 (d, *J* = 6.8 Hz, 3H), 0.88 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (75 MHz, CD₃OD) δ 13.8, 17.6, 17.6, 20.2, 27.2, 33.6, 54.3, 55.7, 61.7, 61.8, 61.8, 116.7 (q, *J* = 36 Hz), 163.1 (q, *J* = 291 Hz), 172.0, 176.4. IR (KBr): 3430 (s), 1754 (w), 1673 (s), 1201 (s), 1136 (m). Mp 134–135 °C. [α]²⁰_D 91.8 (*c* 0.7, MeOH). HRMS (EI⁺): Calcd. for C₁₀H₁₉N₂O₃ [M+H⁺−TFA] 215.1396 Found 215.1389.

Preparation of the crystal.

To a solution of *cis*-pyVal-Pro-NH₂ in MeOH (2 mL) was added heptane (1 mL) and the mixture was allowed to evaporate over three days. The formed crystals were washed with Heptane (2 x 3 mL) and dried in a vacuum oven (50 °C).

X-ray Crystal Structure Determinations.

The crystal of the compound, C₁₂H₂₁N₃O₂·1.5 H₂O, was cooled to 120 K using a Cryostream nitrogen gas cooler system. The data were collected on a Bruker SMART 1K diffractometer with a CCD area sensitive detector. The structure was solved by direct methods and refined by full-matrix least-squares against *F*² of all data. The temperature factors of N1, C3, C4 and C10 are rather large and may indicate that the atoms are disordered. The non-hydrogen atoms were refined anisotropically. The hydrogen atoms of the water molecules were all refined isotropically. All the other hydrogen atoms were at calculated positions using a riding model with C-H = 0.98–1.00 Å, N-H = 0.88 Å. For all hydrogen atoms the thermal parameters were fixed [*U*_{iso}(H) = 1.5 *U*_{iso}(C) for methyl and water and *U*_{iso}(H) = 1.2 *U*_{iso}(C,N) for the remaining H atoms]. The absolute configuration of the structure could not be determined due to the lack of heavy atoms. In the refinement of the structure 2 restraints were used to fix the origin and 4 were used to keep the O-H bonds around 0.9 Å for the water molecules. Programs used for data collection, data reduction and absorption were SMART, SAINT and SADABS.^{ii,iii} The program SHELXTL 95^{iv} was used to solve the structures and for molecular graphics.

Crystal data: *M*= 266.34, tetragonal, *a* = 12.9386(8) Å, *b* = 12.9386(8) Å, *c* = 8.5628(7) Å, *V* = 1433.48(17) Å³, *T* = 120(2) K, space group P4₂, *Z* = 4, *D*_x = 1.234 g cm^{−3}, crystal size = 0.46 x 0.08 x 0.04 mm³, $\mu(\text{MoK}\alpha)$ = 0.091 mm^{−1}, 20006 reflections measured, 1858 unique (*R*_{int} = 0.08(4)) and 1779 reflections with *I* > 2σ(*I*) which were used in all calculations. Friedel pairs were merged before refinement. The final *R*1 was 0.1025 (observed data) and *wR*(*F*²) was 0.2087 (all data).

ⁱ Hosseini, M.; Kringselum, H.; Murray, A.; Tønder, J. E. *Org. Lett.* **2006**, 8, 2103.

ⁱⁱ Sheldrick, G.M. (2001). SADABS. Version 2.03. University of Göttingen, Germany.

ⁱⁱⁱ Bruker (1998). SMART and SAINT. Version 5.054. Bruker AXS Inc., Madison, Wisconsin, USA.

^{iv} Sheldrick, G. M. (2001). SHELXTL. Version 6.12. Bruker AXS Inc., Madison, Wisconsin, USA.